Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Complete Genomics GNOM DNA analysis for human genome -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (7)	9/16/2011 7:48:28 AM
From: idos	Read Replies (1) \| Respond to of 45

>There are 6,000,000,000 people so there's a lot of demand at the right price< If you take a look at GNOM's costumers list you won't find 'people' there, rather the research community - big academic centers, institutions, and agencies. GNOM is focused on whole genome sequencing services and it is not alone. ILMN has it's own service network and is competing on price for large projects and BGI is another player that cannot be ignored. Agree about your point that when the price is low enough, demand will increase but at current price and budgets cut, impact to GNOM might be negative near term. >once the price is right, then medical treatments will probably follow< Potential is there but not likely without having a CLIA certification (ILMN does have one) in a year or so.

To: Maurice Winn who wrote (7)	9/16/2011 10:56:44 PM
From: Maurice Winn	1 Recommendation Respond to of 45

Complete Genomics is totally focused on people: <Also, animal breeders could probably use the information to get high precision in their breeding programmes instead of luck of the draw > From the profile of Complete Genomics: futuremedicine.com <Complete Genomics Inc. is a life sciences company that focuses on complete human genome sequencing. It is taking a completely different approach to DNA sequencing than other companies in the industry. Rather than building a general-purpose platform for sequencing all organisms and all applications, it has focused on a single application – complete human genome sequencing. > In decades to come, they could expand, but the big money is probably in people - though getting a really good kind of wheat, corn, or rice would be pretty good too. It's a wide open field. The quality control for human production is appalling. Taking out the guesswork would be a great help to mothers. Mqurice